Arcutis Biotherapeutics Inc (ARQT)

NASD · Healthcare · Biotechnology · USA

Arcutis Biotherapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company that develops and commercializes treatments for dermatological diseases. The company markets ZORYVE, a topical and systemic treatment for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, available in the United States and Canada. Arcutis also has ARQ-234, a checkpoint agonist in development for atopic dermatitis and other inflammatory conditions.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Arcutis Biotherapeutics Inc stock.

Our verdict on ARQT

Fairly valued: intrinsic value $28.16 per share, market price $27.33, margin of safety 3.0% (as of 2026-11-17).

A 7.1x revenue multiple, discounted for its losses, values the shares at $28.16; the price of $27.33 is 3% below that value.

ETFs with the most weight in ARQT

17 more funds hold it; the full list is part of the paid plan.

More on ARQT

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than ARQT in Biotechnology

20 more in this industry show a wider margin of safety.

Is ARQT undervalued or overvalued?

ARQT is fairly valued (as of the 2026-11-17 close). A 7.1x revenue multiple, discounted for its losses, values the shares at $28.16; the price of $27.33 is 3% below that value.

What is the intrinsic value of ARQT?

$28.16 per share (as of the 2026-11-17 close), against a market price of $27.33. That is a margin of safety of 3.0%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.